ADMA Biologics Q3 2023: first-time net income $2.6M, revenue $67.3M (+64% YoY), raises FY guidance

ADMA BIOLOGICS, INC.

2023-Q3 EPS reported -$0.05 revenue$184,311,323

Total revenues $67.3M, up 64% YoY; first-time positive GAAP net income of $2.6M (vs $14.9M loss YoY).
Adjusted EBITDA grew to $12.7M, up 98% QoQ; first-time positive operating cash flow of $12.0M; cash balance $74.2M.
Gross margin improved to 36.6% from 23.5% YoY; net leverage ratio improved to 1.6x.
FY2023 revenue guidance raised to >$250M; FY2024 >$290M; FY2025 >$335M (from $240M, $275M, $320M previously).
Targets consolidated gross margin 40-50% and net income margin 20-30% in 2024-2025; ongoing strategic review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ADMA BIOLOGICS, INC. reported three months ended September 30, 2023 results: revenue $67.3 Million, net income $2.6 Million. Guidance raised.

Period: three months ended September 30, 2023
Revenue: $67.3 Million
Net income: $2.6 Million
Guidance: raised
Result: reported results

Exact text from the filing

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update 3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-052102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.